CLD 301
Alternative Names: CLD-301Latest Information Update: 13 Jun 2023
At a glance
- Originator Calidi Biotherapeutics
- Class Immunotherapies; Mesenchymal stem cell therapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 08 Jun 2023 Preclinical trials in Unspecified in USA (IV) as of June 2023 (Calidi Biotherapeutics pipeline, June 2023)